Top-News
Professionelle Dienstleistungen USA

Acurx Pharmaceuticals News

Aktie
WKN:  A3CSCG ISIN:  US00510M1045 US-Symbol:  ACXP
1,79 €
-0,29 €
-13,94%
08.04.24 19:49:00
Handeln Depot/Watchlist
Aktienanzahl *
13,01 Mio.
Marktkapitalisierung *
26,93 Mio. €
Streubesitz
-
Index-Zugehörigkeit
-
IR-Website
zur Website
*Stand: 09.10.2023

Acurx Pharmaceuticals News

15.05.24 - PR Newswire
Acurx Announces Successful FDA End-of-Phase 2 Meeting and Phase 3 Readiness for Ibezapolstat in the Treatment of C. difficile Infection
Acurx Announces Successful FDA End-​of-Phase 2 Meeting and Phase 3 Readiness for Ibezapolstat in the Treatment of C. difficile Infection PR Newswire
15.05.24 - PR Newswire
Acurx Pharmaceuticals, Inc. Reports First Quarter 2024 Results and Provides Business Update
Acurx Pharmaceuticals, Inc. Reports First Quarter 2024 Results and Provides Business Update PR Newswire
02.05.24 - PR Newswire
Acurx Pharmaceuticals Announces Presentation of Ibezapolstat Phase 2 Clinical Trial Results at ESCMID Global 2024 Scientific Conference
Acurx Pharmaceuticals Announces Presentation of Ibezapolstat Phase 2 Clinical Trial Results at ESCMID Global 2024 Scientific Conference PR Newswire
25.04.24 - PR Newswire
Acurx Pharmaceuticals Announces Presentation of Ibezapolostat Phase 2 Clinical Trial Results at upcoming ESCMID 2024 Scientific Conference
Acurx Pharmaceuticals Announces Presentation of Ibezapolostat Phase 2 Clinical Trial Results at upcoming ESCMID 2024 Scientific Conference PR Newswire
23.04.24 - PR Newswire
Acurx Pharmaceuticals, Inc. to Discuss First Quarter 2024 Financial Results on May 15, 2024 Conference Call and Provide Business Update
Acurx Pharmaceuticals, Inc. to Discuss First Quarter 2024 Financial Results on May 15, 2024 Conference Call and Provide Business Update PR Newswire
18.03.24 - PR Newswire
Acurx Pharmaceuticals, Inc. Reports Fourth Quarter and Full Year 2023 Results and Provides Business Update
Acurx Pharmaceuticals, Inc. Reports Fourth Quarter and Full Year 2023 Results and Provides Business Update PR Newswire
04.03.24 - PR Newswire
Acurx Pharmaceuticals, Inc. to Discuss Fourth Quarter and Full Year 2023 Financial Results on March 18, 2024 Conference Call and Provide Business Update
Acurx Pharmaceuticals, Inc. to Discuss Fourth Quarter and Full Year 2023 Financial Results on March 18, 2024 Conference Call and Provide Business Update PR Newswire
27.02.24 - PR Newswire
Acurx Announces FDA Has Granted an End of Phase 2 Meeting for Ibezapolstat for C. difficile Infection and the European Medicines Agency Granted SME Designation for Ibezapolstat EU Development
Acurx Announces FDA Has Granted an End of Phase 2 Meeting for Ibezapolstat for C. difficile Infection and the European Medicines Agency Granted SME Designation for ...
29.01.24 - PR Newswire
Acurx Announces Positive Extended Clinical Cure Data for Ibezapolstat from Phase 2b Clinical Trial in CDI Patients
Acurx Announces Positive Extended Clinical Cure Data for Ibezapolstat from Phase 2b Clinical Trial in CDI Patients PR Newswire
23.01.24 - PR Newswire
Acurx Pharmaceuticals to Present at the Microcap Conference, January 31, 2024 - February 1, 2024
Acurx Pharmaceuticals to Present at the Microcap Conference, January 31, 2024 - February 1, 2024 PR Newswire
17.01.24 - PR Newswire
Thinking about buying stock in Endeavour Silver, Exxon Mobil, Sealsq Corp, Fusion Pharmaceuticals, or Acurx Pharmaceuticals?
Thinking about buying stock in Endeavour Silver, Exxon Mobil, Sealsq Corp, Fusion Pharmaceuticals, or Acurx Pharmaceuticals? PR Newswire
17.01.24 - PR Newswire
Acurx Announces Positive Comparative Microbiology and Microbiome Data for Ibezapolstat from Phase 2b Clinical Trial in CDI Patients
Acurx Announces Positive Comparative Microbiology and Microbiome Data for Ibezapolstat from Phase 2b Clinical Trial in CDI Patients PR Newswire
03.01.24 - PR Newswire
Acurx to present at the 42nd Annual J.P. Morgan Healthcare Conference
Acurx to present at the 42nd Annual J.P. Morgan Healthcare Conference PR Newswire
12.12.23 - PR Newswire
Thinking about buying stock in Crispr Therapeutics, Ardelyx, ADC Therapeutics, Acurx Pharmaceuticals, or Sphere 3D?
Thinking about buying stock in Crispr Therapeutics, Ardelyx, ADC Therapeutics, Acurx Pharmaceuticals, or Sphere 3D? PR Newswire
11.12.23 - PR Newswire
Acurx Announces Positive Phase 2b Results Showing 100% of Patients Who Had Clinical Cure with Ibezapolstat Also Had Sustained Clinical Cure
Acurx Announces Positive Phase 2b Results Showing 100% of Patients Who Had Clinical Cure with Ibezapolstat Also Had Sustained Clinical Cure PR Newswire
02.11.23 - PR Newswire
Acurx Announces Positive Top-Line Ibezapolstat Phase 2 Efficacy Results with 96% Clinical Cure Rate in Patients with C. difficile Infection
Acurx Announces Positive Top-Line Ibezapolstat Phase 2 Efficacy Results with 96% Clinical Cure Rate in Patients with C. difficile Infection PR Newswire
25.10.23 - PR Newswire
Acurx Pharmaceuticals to Discuss Third Quarter 2023 Financial Results and Provide Business Update
Acurx Pharmaceuticals to Discuss Third Quarter 2023 Financial Results and Provide Business Update PR Newswire
19.10.23 - PR Newswire
Acurx Announces Ibezapolstat Scientific Posters and Presentations at ClostPath 2023 and IDWeek 2023 Scientific Conferences
Acurx Announces Ibezapolstat Scientific Posters and Presentations at ClostPath 2023 and IDWeek 2023 Scientific Conferences PR Newswire
11.10.23 - PR Newswire
Thinking about buying stock in Profrac Holding, Camber Energy, Acurx Pharmaceuticals, 89bio, or SuperCom Ltd.?
Thinking about buying stock in Profrac Holding, Camber Energy, Acurx Pharmaceuticals, 89bio, or SuperCom Ltd.? PR Newswire
03.10.23 - PR Newswire
Thinking about buying stock in Kosmos Energy, BioLine RX, BTCS Inc, OSI Systems, or Acurx Pharmaceuticals?
Thinking about buying stock in Kosmos Energy, BioLine RX, BTCS Inc, OSI Systems, or Acurx Pharmaceuticals? PR Newswire

Newssuche

Videos

newspaper
17.05.24 +14,15%
Technical Trading: Gold Long-​Chance
Gold Long Typ: Turbo Open End WKN: VD1G7Y Hebel: 10 Laufzeit: OpenEnd Einstieg: Market ... Mehr »